Professional Summary
Professional Overview
Steven Shallcross is an experienced chief executive officer, chief financial officer, and director with a proven track record of leadership and financial management across the pharmaceutical and technology industries. He currently serves as the CEO, CFO, and Director of Theriva Biologics, Inc., a clinical-stage biopharmaceutical company focused on developing novel therapies for gastrointestinal diseases.
Experience Summary
Current Role
As the CEO, CFO, and Director of Theriva Biologics, Inc., Mr. Shallcross is responsible for overseeing the company's strategic direction, financial operations, and governance. He has been instrumental in guiding the company through its transition and growth, including securing funding, managing clinical trials, and advancing the company's pipeline of therapeutic candidates.
Career Progression
Throughout his 30+ year career, Mr. Shallcross has held various senior-level finance and executive roles at both public and private companies, including Elys Game Technology Corp., Twin Vee PoweCats, Nuo Therapeutics, Inc., Empire Petroleum Partners, LLC, Innocoll Pharmaceuticals, Vanda Pharmaceuticals, and MiddleBrook Pharmaceuticals, Inc. He has a proven track record of driving financial performance, implementing operational efficiencies, and leading successful business transformations.
Academic Background
Mr. Shallcross holds a Bachelor of Science degree in Accounting from Lehigh University.
Areas of Expertise
- Financial management and reporting
- Strategic planning and business transformation
- Operational optimization and efficiency
- Regulatory compliance and corporate governance
- Fundraising and investor relations
Professional Impact
Under Mr. Shallcross's leadership, Theriva Biologics has successfully advanced its pipeline of innovative therapeutic candidates, secured additional funding, and strengthened its position as a leader in the gastrointestinal disease treatment space. His extensive experience in the pharmaceutical and technology industries, coupled with his strong financial acumen and strategic vision, have been instrumental in driving the company's growth and creating value for its stakeholders.
Conclusion
With his diverse experience, proven leadership skills, and deep understanding of the industries he serves, Steven Shallcross is well-positioned to continue guiding Theriva Biologics through its next phase of growth and development. His commitment to driving innovation and delivering results make him a valuable asset to the companies and communities he serves.
